Literature DB >> 7053864

Relationship between natural killer cell activity and histological features of lymphocyte infiltration and partial regression of the primary tumor in melanoma patients.

P Hersey, A Hobbs, A Edwards, W H McCarthy, V J McGovern.   

Abstract

A group of 194 melanoma patients with Stage I melanoma was studied in an attempt to correlate histological features of prognostic importance in malignant melanoma with the level of natural killer cell (NK) activity in blood mononuclear cells. Histological features examined were lymphocytic infiltrate of the tumor base, lymphocyte infiltration at the tumor margin, and evidence of partial regression in the tumor. NK activity against melanoma cells and non-melanoma cells was studied in the same patients before and after surgical removal of melanoma. Patients with high NK activity against melanoma and Chang cells had less lymphocyte infiltrate at the base of the tumor irrespective of its thickness than did those with low NK activity. Patients with low NK activity and thin tumors had more lymphocyte infiltration at the base of the tumor than did those with high NK activity. Similar results were obtained in certain subsets of cases with respect to lymphocytic infiltration at the tumor margins and to the presence of partial regression. Although the nature of the association between these histological features and NK activity in blood is unknown, it is suggested that previously unexplained associations between histological features and prognosis may be accounted for by their association with NK activity. If this proves to be correct, measurement of NK activity may be an important additional prognostic factor in patients with melanoma.

Entities:  

Mesh:

Year:  1982        PMID: 7053864

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging.

Authors:  Judith Eckl; Alexander Buchner; Petra U Prinz; Rainer Riesenberg; Sabine I Siegert; Robert Kammerer; Peter J Nelson; Elfriede Noessner
Journal:  J Mol Med (Berl)       Date:  2011-08-26       Impact factor: 4.599

2.  Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.

Authors:  W H de Jong; P A Steerenberg; J G Kreeftenberg; R H Tiesjema; W Kruizinga; L M van Noorle Jansen; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients.

Authors:  P Hersey; A Edwards; G D'Alessandro; M MacDonald
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Suppression of peripheral blood natural killer cell activity by excess thyroid hormone.

Authors:  M Papic; J Stein-Streilein; M Zakarija; J M McKenzie; J Guffee; M A Fletcher
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

5.  Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract.

Authors:  E Lotzová; C A Savary; R S Freedman; J M Bowen
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 6.  Natural killer cells in human solid tumors.

Authors:  M Introna; A Mantovani
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

7.  CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α.

Authors:  Lazar Vujanovic; Christopher Chuckran; Yan Lin; Fei Ding; Cindy A Sander; Patricia M Santos; Joel Lohr; Afshin Mashadi-Hossein; Sarah Warren; Andy White; Alan Huang; John M Kirkwood; Lisa H Butterfield
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.